Genetically engineered human neural stem cells with rabbit carboxyl esterase can target brain metastasis from breast cancer

Cancer Letters

Volumn 311, Issue 2, 2011, Pages 152-159

  Seol, Ho Jun ^a   Jin, Juyoun ^a,b   Seong, Dong Ho ^c   Joo, Kyeung Min ^a,b,d   Kang, Wonyoung ^a,b   Yang, Heekyoung ^a,b   Kim, Jandi ^d   Shin, Chul Soo ^c   Kim, Yonghyun ^a,b   Kim, Kang Ho ^a,b   Kong, Doo Sik ^a   Lee, Jung II ^a   Aboody, Karen S ^e   Lee, Hong Jun ^f,g   Kim, Seung U ^f,g   Nam, Do Hyun ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Yonsei University   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g Chung Ang University College of Medicine   (South Korea)

Author keywords

Carboxyl esterase (CE); CPT 11; Metastatic brain tumor

Indexed keywords

CARBOXYLESTERASE; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER GENE THERAPY; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; DRUG TARGETING; GENETIC ENGINEERING; HUMAN; HUMAN CELL; MOUSE; NEURAL STEM CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RABBIT; SURVIVAL RATE; TUMOR VOLUME;

ANIMALS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARBOXYLESTERASE; FEMALE; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC ENGINEERING; HUMANS; MICE; MICE, INBRED BALB C; NEURAL STEM CELLS; RABBITS;

MUS; ORYCTOLAGUS CUNICULUS;

EID: 84860388865     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.07.001     Document Type: Article

References (32)

1. Biswas G., Bhagwat R., Khurana R., Menon H., Prasad N., Parikh P.M. Brain metastasis-evidence based management. J. Cancer Res. Ther. 2006, 2:5-13.
2. Chang S.D., Adler J.R. Current treatment of patients with multiple brain metastases. Neurosurg. Focus 2000, 9:e5.
3. Shaffrey M.E., Mut M., Asher A.L., Burri S.H., Chahlavi A., Chang S.M., Farace E., Fiveash J.B., Lang F.F., Lopes M.B., Markert J.M., Schiff D., Siomin V., Tatter S.B., Vogelbaum M.A. Brain metastases. Curr. Probl. Surg. 2004, 41:665-741.
4. Kennecke H., Yerushalmi R., Woods R., Cheang M.C., Voduc D., Speers C.H., Nielsen T.O., Gelmon K. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 2010, 28:3271-3277.
5. Aboody K.S., Najbauer J., Schmidt N.O., Yang W., Wu J.K., Zhuge Y., Przylecki W., Carroll R., Black P.M., Perides G. Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro. Oncol. 2006, 8:119-126.
6. Schmidt N.O., Przylecki W., Yang W., Ziu M., Teng Y., Kim S.U., Black P.M., Aboody K.S., Carroll R.S. Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. Neoplasia 2005, 7:623-629.
7. Gutova M., Najbauer J., Chen M.Y., Potter P.M., Kim S.U., Aboody K.S. Therapeutic targeting of melanoma cells using neural stem cells expressing carboxylesterase, a CPT-11 activating enzyme. Curr. Stem Cell Res. Ther. 2010, 5:273-276.
8. Kim K.Y., Kim S.U., Leung P.C., Jeung E.B., Choi K.C. Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth. Cancer Sci. 2010, 101:955-962.
9. Aboody K.S., Bush R.A., Garcia E., Metz M.Z., Najbauer J., Justus K.A., Phelps D.A., Remack J.S., Yoon K.J., Gillespie S., Kim S.U., Glackin C.A., Potter P.M., Danks M.K. Development of a tumor-selective approach to treat metastatic cancer. PLoS ONE 2006, 1:e23.
10. Lee H.J., Kim K.S., Kim E.J., Choi H.B., Lee K.H., Park I.H., Ko Y., Jeong S.W., Kim S.U. Brain transplantation of immortalized human neural stem cells promotes functional recovery in mouse intracerebral hemorrhage stroke model. Stem Cells 2007, 25:1204-1212.
11. Aboody K.S., Brown A., Rainov N.G., Bower K.A., Liu S., Yang W., Small J.E., Herrlinger U., Ourednik V., Black P.M., Breakefield X.O., Snyder E.Y. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl. Acad. Sci. USA 2000, 97:12846-12851.
12. Potter P.M., Pawlik C.A., Morton C.L., Naeve C.W., Danks M.K. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). Cancer Res. 1998, 58:2646-2651.
13. Joo K.M., Park I.H., Shin J.Y., Jin J., Kang B.G., Kim M.H., Lee S.J., Jo M.Y., Kim S.U., Nam D.H. Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. Mol. Ther. 2009, 17:570-575.
14. Kim S.K., Kim S.U., Park I.H., Bang J.H., Aboody K.S., Wang K.C., Cho B.K., Kim M., Menon L.G., Black P.M., Carroll R.S. Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin. Cancer Res. 2006, 12:5550-5556.
15. Danks M.K., Yoon K.J., Bush R.A., Remack J.S., Wierdl M., Tsurkan L., Kim S.U., Garcia E., Metz M.Z., Najbauer J., Potter P.M., Aboody K.S. Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res. 2007, 67:22-25.
16. van den Bent M.J., Hegi M.E., Stupp R. Recent developments in the use of chemotherapy in brain tumours. Eur. J. Cancer 2006, 42:582-588.
17. Prados M.D., Lamborn K., Yung W.K., Jaeckle K., Robins H.I., Mehta M., Fine H.A., Wen P.Y., Cloughesy T., Chang S., Nicholas M.K., Schiff D., Greenberg H., Junck L., Fink K., Hess K., Kuhn J. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American brain tumor consortium study. Neuro. Oncol. 2006, 8:189-193.
18. Poulsen H.S., Grunnet K., Sorensen M., Olsen P., Hasselbalch B., Nelausen K., Kosteljanetz M., Lassen U. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol. 2009, 48:52-58.
19. Quinn J.A., Jiang S.X., Reardon D.A., Desjardins A., Vredenburgh J.J., Friedman A.H., Sampson J.H., McLendon R.E., Herndon J.E., Friedman H.S. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. J. Neurooncol. 2009, 95:393-400.
20. de Groot J.F., Yung W.K. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J. 2008, 14:279-285.
21. Kang Y. Analysis of cancer stem cell metastasis in xenograft animal models. Methods Mol. Biol. 2009, 568:7-19.
22. Cranmer L.D., Trevor K.T., Bandlamuri S., Hersh E.M. Rodent models of brain metastasis in melanoma. Melanoma Res. 2005, 15:325-356.
23. Wang J., Daphu I., Pedersen P.H., Miletic H., Hovland R., Mork S., Bjerkvig R., Tiron C., McCormack E., Micklem D., Lorens J.B., Immervoll H., Thorsen F. A novel brain metastases model developed in immunodeficient rats closely mimics the growth of metastatic brain tumours in patients. Neuropathol. Appl. Neurobiol. 2011, 37:189-205.
24. Bongso A., Fong C.Y., Gauthaman K. Taking stem cells to the clinic: major challenges. J. Cell. Biochem. 2008, 105:1352-1360.
25. Sandu N., Schaller B. Stem cell transplantation in brain tumors: a new field for molecular imaging?. Mol. Med. 2010, 16:433-437.
26. Kim S.U., de Vellis J. Stem cell-based cell therapy in neurological diseases: a review. J. Neurosci. Res. 2009, 88:2183-2200.
27. Kim S.U. Human neural stem cells genetically modified for brain repair in neurological disorders. Neuropathology 2004, 24:159-171.
28. Park I.H., Zhao R., West J.A., Yabuuchi A., Huo H., Ince T.A., Lerou P.H., Lensch M.W., Daley G.Q. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451:141-146.
29. Hermann A., Gastl R., Liebau S., Popa M.O., Fiedler J., Boehm B.O., Maisel M., Lerche H., Schwarz J., Brenner R., Storch A. Efficient generation of neural stem cell-like cells from adult human bone marrow stromal cells. J. Cell Sci. 2004, 117:4411-4422.
30. Huang Q., Liu X.Z., Kang C.S., Wang G.X., Zhong Y., Pu P.Y. The anti-glioma effect of suicide gene therapy using BMSC expressing HSV/TK combined with overexpression of Cx43 in glioma cells. Cancer Gene Ther. 2010, 17:192-202.
31. Ahmed A.U., Alexiades N.G., Lesniak M.S. The use of neural stem cells in cancer gene therapy: predicting the path to the clinic. Curr. Opin. Mol. Ther. 2010, 12:546-552.
32. Aboody K.S., Najbauer J., Danks M.K. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther. 2008, 15:739-752.